Biopharma Partnering and M&A Activity in 2011 Discussed in New Report Published at MarketPublishers.com

Share Article

The world of biopharma industry has become increasingly reliant on smaller biotech firms to help provide new products to feed its R&D pipelines. New research report “Partnering and M&A Yearbook 2012” elaborated by CurrentPartnering has been recently published by Market Publishers Ltd.

marketpublishers.com

Market Publishers Ltd

The world biopharma industry has become increasingly reliant on smaller biotech firms to help provide new products to feed its R&D pipelines. In the battle for deals, what does it take to come out a winner? The study helps illuminate the attributes of an ideal partner as well as outlines which companies are living up to these expectations.

New research report “Partnering and M&A Yearbook 2012” elaborated by CurrentPartnering has been recently published by Market Publishers Ltd.

Report Details:

Title: Partnering and M&A Yearbook 2012
Published: January, 2012
Pages: 5000
Price: US$ 3,495
http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/healthcare_equipment_services/partnering_n_ma_yearbook_2012.html

The report is aimed at providing comprehensive understanding and unprecedented access to a wide range of partnering and M&A deals and agreements entered into by the top healthcare companies from pole to pole during 2011, as well as presenting forecasts for dealmaking in 2012.

Report Scope:

  •     trends in dealmaking in the biopharma industry since 2007;
  •     analysis of partnering and M&A deal structure;
  •     comprehensive directory of partnering and M&A deals in 2011;
  •     links to online access to over 3,500 partnering and 600 M&A deals;
  •     the leading partnering and M&A deals by value in 2011;
  •     most active partnering and M&A dealmakers during 2011.

Report Contents:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Overview of Partnering Activity in 2011

2.1. Introduction
2.2. Partnering activity in 2011
2.2.1. Partnering activity by volume
2.2.2. Partnering activity by deal dollars
2.3. Key partnering deals of 2011 – The top 10
2.3.1. Eli Lilly – Boehringer Ingelheim: Licensing, development and option agreement to co-market and co-develop insulin analogues
2.3.2. Lundbeck – Otsuka: Co-development and co-promotion agreement for up to five innovative psychiatric and neuroscience products
2.3.3. Eli Lilly – Amylin: Termination agreement for Bydureon (exenatide) once-weekly
2.3.4. Alios Biopharma – Vertex: Licensing agreement for ALS-2200 and ALS-2158
2.3.5. Astellas – Aveo Pharmaceuticals: Collaborative R&D and commercialisation agreement for tivozanib
2.3.6. Emergent BioSolutions – US Government: Contract service and supply agreement for BioThrax
2.3.7. Amgen – Micromet: Collaborative R&D agreement for BiTE antibodies against three undisclosed solid tumor targets
2.3.8. Servier – mirage: Development agreement for miR-208 and miR-15/195 plus additional target
2.3.9. Janssen Biotech – Pharmacyclics: Co-development, licensing and marketing agreement for PCI-32765
2.3.10. China Meheco: Supply agreement for drugs to Venezuela
2.4. Biopharma partnering deals
2.5. Partnering deals by industry sector
2.6. Partnering deals by stage development
2.7. Partnering deals by deal type
2.8. Partnering deals by therapy area
2.9. Partnering deal terminations in 2011

Chapter 3 – Overview of M&A Activity in 2011

3.1. Introduction
3.2. M&A deals of 2011
3.2.1. M&A activity by volume
3.2.2. M&A activity by deal dollars
3.3. Key M&A deals of 2011 – The top 10
3.3.1. Express Scripts – Medco Health Solutions: Acquisition agreement for Medco Health Solutions
3.3.2. Johnson & Johnson – Synthes: Acquisition agreement for Synthes
3.3.3. Takeda – Nycomed: Acquisition agreement for Nycomed
3.3.4. Gilead Sciences – Pharmasset: Acquisition agreement for Pharmasset
3.3.5. Danaher – Beckman Coulter: Acquisition agreement for Beckman Coulter
3.3.6. Teva – Cephalon: Acquisition agreement for Cephalon
3.3.7. DuPont – Danisco: Acquisition agreement for Danisco
3.3.8. Kinetic Concepts – Apax Partners: Acquisition agreement for Kinetic Concepts
3.3.9. PPD – Carlyle Group – Hellman & Friedman: Acquisition agreement for PPD
3.3.10. Thermo Fisher Scientific – Phadia: Acquisition agreement for Phadia
3.4. Bigpharma M&A deals of 2011
3.5. M&A deals by industry sector in 2011

Chapter 4 – Most Active Dealmakers in 2011

4.1. Introduction
4.2. Partnering – most active in 2011
4.3. M&A – most active in 2011

Chapter 5 – Top Deals by Value in 2011

5.1. Introduction
5.2. Top partnering deals in 2011
5.3. Top M&A deals in 2011

Chapter 6 – Bigpharma Partnering in 2011

6.1. Introduction
6.2. Bigpharma partnering by industry sector
...

More new research reports by the publisher can be found at CurrentPartnering page.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tanya Rezler
Visit website